BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
水曜日, 9 30

Halozyme Therapeutics Inc

HALONASDAQ
Trade with Public
Trade with Public
$111.56
-1.33-1.18%
近くで: Sep 29, 5:00 PM EST
$111.56
N/A
時間外: 4:01 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Halozyme Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Halozyme Therapeutics (HALO).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

2S.Buy
5Buy
3Hold
Consensus RatingMarket Outperform# Analysts10Avg. Consensus PT$83Upside to Avg. PT-26.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$115
Aug 7, 2026Leerink PartnersDavid RisingerUpgradeMarket Perform→Outperform$83→$110
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $115 price target.
Benzinga Newsdesk

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $92 to $93.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $75 to $95.
Benzinga Newsdesk

Atlassian To Rally More Than 63%? Here Are 10 Top Analyst Forecasts For Friday

Wall Street analysts changed ratings & price targets for top stocks. Check out all changes including upgrades & downgrades on Benzinga analyst ratings page.
Avi Kapoor

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved